MPMontserrat Puig

Montserrat Puig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Montserrat Puig has a total of 123 co-authors. Here are the top co-authors by number of shared publications:

  • Marco Cardone

    Division of Pharmaceutical Quality Research IV, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, United States

    4 shared publications
  • Michael A. Norcross

    Division of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, United States

    4 shared publications
  • Amy S. Rosenberg

    Laboratory of Immunology, Division of Biotechnology Review and Research III (DBRR III), Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), FDA, Silver Spring, MD, United States

    3 shared publications
  • Daniela Verthelyi

    Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, USA

    3 shared publications
  • Gregory Roderiquez

    Laboratory of Immunology, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Md

    3 shared publications
  • Kirthiram Krishnaveni Sivakumar

    Division of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA

    3 shared publications

Latest Publications

  • Proceedings of the 2024 FDA-CRCG Workshop: Scientific and Regulatory Considerations for Assessment of Immunogenicity Risk for Generic Peptide and Oligonucleotide Drug Products

    by Jennifer K. Lee, Ha-Na Lee, Sudhir Agrawal, Joseph A. Balsamo, Andrew Clerman, Sofie Denies, Anne De Groot, Jeremy Fry, Nicolas Gaudenzio, Andrew J. Graves, et al.

    On Oct 7 and 8, 2024, the US Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a workshop titled “S

  • Open Access

    Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA ‐Transgenic Mice

    by SuJin Hwang, Telly Sepahpour, Stephanie Kortchak, Kirthiram Krishnaveni Sivakumar, Spyros Karaiskos, Ngoc Pham, Yura Jang, Montserrat Puig, Michael Norcross

    Background: Abacavir (ABC)‐induced hypersensitivity is associated with HLA‐B*57:01, with tolerance maintained by regulatory T cells (Treg). This study hypothesized that the balance between Treg and CD8 + T‐cells is influenced by the level of human leucocyte antigen (HLA) expression to determine hypersensitivity versus tolerance to abacavir. Methods: HLA‐B*57:01 transgenic (Tg) mice and Tg mice lacking H2‐K b D b (Tg/KO) were treated with ABC with or without IFN‐α or IFN‐γ blockade. Immune cell phenotype and functions were assessed via flow cytometry, and splenic transcriptomic profiles were analyzed to evaluate gene expression changes associated with treatment. Results: ABC treatment of Tg/KO mice, which only express HLA‐B*57:01 as an MHC‐I allele, led to the expansion of drug‐specific CD8 + T‐cells, enhanced antigen presenting cell (APC) activity, and reduction in Tregs. These changes were accompanied by increased IFN‐α levels and plasmacytoid dendritic cell (pDC) maturation. Depletion of pDCs or blocking of IFN‐αR, in contrast to IFN‐γ blockade, restored Treg populations and diminished CD8 + T‐cell responses. These findings demonstrate that IFN‐α, primarily produced by pDCs, disrupts Treg expansion, whereas IFN‐γ predominantly enhances APC maturation and activation. Transcriptomic analysis revealed key genes regulated exclusively by ABC treatment in the presence of both IFN‐α and IFN‐γ signaling and demonstrated that IFN‐α signaling predominantly modulates innate and adaptive immune genes while supporting the downregulation of Treg‐related genes. Conclusions: In vivo upregulation of HLA expression modulates the balance between drug‐specific and regulatory T cells, thereby promoting optimal pDC expansion and enhancing IFN‐α production, which counteracts Treg‐mediated ABC tolerance. IFN‐γ secretion by drug‐specific CD8 + T‐cells promoted APC and effector T‐cell function that led to the development of ABC‐associated hypersensitivity reactions in immunocompetent HLA Tg mice.


  • Top Cited Papers
    Open Access

    Immunogenicity of therapeutic peptide products: bridging the gaps regarding the role of product-related risk factors

    by Montserrat Puig, Sophie Shubow

    The global market for therapeutic peptides is projected to continue to grow at a fast pace in the coming years in response to high demand for these products. The increasing complexity of chemical and recombinant peptide manufacturing processes may impact product quality attributes, including as related to immunogenicity risk. While it is well established that product-related factors, including impurities, can impact the immunogenicity of a biologic product, assessing the actual impact of a specific product quality attribute on immunogenicity is difficult. Despite significant advances in the analytical characterization of complex peptide products, gaps still exist in our understanding of the significance of impurities to the overall peptide immunogenicity risk, and questions remain about what the best-suited control strategies are. These gaps have the largest impact on the assessment of immunogenicity risk of follow-on therapeutic peptide products, when clinical data are not available to inform that risk. Current regulatory guidance on impurity qualification thresholds is sparse, and in vitro and in silico immunogenicity assessment methods for evaluating the immunogenicity risk of impurities present technical and methodological limitations. We highlight these challenges and offer points to consider for handling them.


  • Open Access

    Insights into regulatory T-cell and type-I interferon roles in determining abacavir-induced hypersensitivity or immune tolerance

    by Marco Cardone, Hratch M. Baghdassarian, Maryam Khalaj, Kirthiram Krishnaveni Sivakumar, SuJin Hwang, Sintayehu Gebreyohannes, Kazuyo Takeda, Yura Jang, Nathan E. Lewis, Michael A. Norcross, et al.

    Introduction: Clinical use of several small molecule drugs may lead to severe T-cell-mediated idiosyncratic drug hypersensitivity reactions (iDHR) linked to HLA alleles, including abacavir (ABC) with HLA-B*57:01. Due to study limitations in humans, pathogenic networks in iDHR remain elusive. HLA transgenic murine models have been proposed to bridge knowledge gaps in tolerance and susceptibility to drugs.Methods: Mice expressing HLA-B*57:01 and Foxp3-DTR/EGFP were generated to selectively deplete regulatory T-cells (Treg) with diphtheria toxin. ABC was administered for 8 days alone or together with cell- and cytokine-depleting antibodies. Cellular and transcriptomic responses were analyzed by RNA, flow cytometry and fluorescence methods.Results: While CD8+ T-cell responses to ABC require HLA presentation, ABC also triggered mitochondrial stress in macrophages in vitro, independently of HLA. In vivo, Treg were the primary mechanism of drug tolerance controlling HLA presentation and costimulation by antigen presenting cells. Treg ablation uncovered immune adverse events linked to activation and proliferation of both drug-specific and bystander CD8+ T-cells through CD28-mediated pathways with support from CD4+ non-Treg. Type-I interferon (IFN-I) and cellular-stress pathways influenced the fate of lymph node cells responding to ABC, implicating innate immune cells such as macrophages and plasmacytoid dendritic cells in the development of T-cell responses against the drug. IFN-I and IL-2 were necessary for CD8+ T-cell differentiation and ABC-induced adverse reactions.Conclusions: This study unveils novel immune mechanisms driven by drug and host-related factors required for in vivo reactions and sheds light on potential biomarker and therapeutic targets for managing and preventing severe and life-threatening iDHR.


  • Open Access

    Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules

    by Montserrat Puig, Michael A. Norcross

    Purpose of review: Immune-mediated drug hypersensitivity reactions (DHRs) can be life-threatening and an impediment to drug development. Mechanism of disease studies are difficult to perform in humans. Here we review human leukocyte antigens class I (HLA-I) transgenic murine models and highlight how these systems have helped to elucidate drug-specific and host immune factors that initiate, propagate and control severe drug toxicities to skin and liver. Recent findings: HLA transgenic mice have been developed and used to study immune-mediated drug reactions in vitro and in vivo. CD8+ T cells from HLA-B∗57:01-expressing mice respond strongly to abacavir (ABC) in vitro but have self-limited responses to drug exposure in vivo. Immune tolerance can be overcome by depleting regulatory T cells (Treg) allowing antigen-presenting dendritic cells to express CD80/86 costimulatory molecules and signal through CD28 on the CD8+ T cell. Depletion of Treg also removes competition for interleukin 2 (IL-2) to allow T cell expansion and differentiation. Fine tuning of responses depends on inhibitory checkpoint molecules such as PD-1. Improved mouse models express only HLA in the absence of PD-1. These models show enhanced liver injury to flucloxacillin (FLX) which depends on drug priming, CD4+ T cell depletion, and lack of PD-1 expression. Drug-specific HLA-restricted cytotoxic CD8+ T cells can infiltrate the liver but are suppressed by Kupffer and liver sinusoidal endothelial cells. Summary: HLA-I transgenic mouse models are now available to study ABC, FLX and carbamazepine-induced adverse reactions. In vivo studies range from characterizing drug-antigen presentation, T cell activation, immune-regulatory molecules and cell-cell interaction pathways that are specifically involved in causing or controlling unwanted DHRs.


  • Open Access

    Development of mouse models with restricted HLA-B∗57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury

    by Suryatheja Ananthula, Kirthiram Krishnaveni Sivakumar, Marco Cardone, Shan Su, Gregory Roderiquez, Hanan Abuzeineh, David E. Kleiner, Michael A. Norcross, Montserrat Puig


  • Open Access

    Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides

    by Montserrat Puig, Suryatheja Ananthula, Ramesh Venna, Swamy Kumar Polumuri, Elliot Mattson, Lacey M. Walker, Marco Cardone, Mayumi Takahashi, Shan Su, Lisa F. Boyd, et al.

    Neoantigen formation due to the interaction of drug molecules with human leukocyte antigen (HLA)-peptide complexes can lead to severe hypersensitivity reactions. Flucloxacillin (FLX), a β-lactam antibiotic for narrow-spectrum gram-positive bacterial infections, has been associated with severe immune-mediated drug-induced liver injury caused by an influx of T-lymphocytes targeting liver cells potentially recognizing drug-haptenated peptides in the context of HLA-B*57:01. To identify immunopeptidome changes that could lead to drug-driven immunogenicity, we used mass spectrometry to characterize the proteome and immunopeptidome of B-lymphoblastoid cells solely expressing HLA-B*57:01 as MHC-I molecules. Selected drug-conjugated peptides identified in these cells were synthesized and tested for their immunogenicity in HLA-B*57:01-transgenic mice. T cell responses were evaluated in vitro by immune assays. The immunopeptidome of FLX-treated cells was more diverse than that of untreated cells, enriched with peptides containing carboxy-terminal tryptophan and FLX-haptenated lysine residues on peptides. Selected FLX-modified peptides with drug on P4 and P6 induced drug-specific CD8+ T cells in vivo. FLX was also found directly linked to the HLA K146 that could interfere with KIR-3DL or peptide interactions. These studies identify a novel effect of antibiotics to alter anchor residue frequencies in HLA-presented peptides which may impact drug-induced inflammation. Covalent FLX-modified lysines on peptides mapped drug-specific immunogenicity primarily at P4 and P6 suggesting these peptide sites as drivers of off-target adverse reactions mediated by FLX. FLX modifications on HLA-B*57:01-exposed lysines may also impact interactions with KIR or TCR and subsequent NK and T cell function.


  • Open Access

    Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

    by Marco Cardone, Masahide Yano, Amy S. Rosenberg, Montserrat Puig

    The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. The disease caused by SARS-CoV-2, termed COVID-19, is multifactorial and associated with both specific antiviral as well as inflammatory responses, the extent of which may determine why some individuals are asymptomatic while others develop serious complications. Here we review possible life-threating immune events that can occur during disease progression to uncover key factors behind COVID-19 severity and provide suggestions for interventions with repurposed drugs in well-controlled and randomized clinical trials. These drugs include therapeutics with potential to inhibit SARS-CoV-2 entry into host cells such as serine protease inhibitors of the cellular protease TMPS2 and drugs targeting the renin-angiotensin system; antivirals with potential to block SARS-CoV-2 replication or factors that could boost the antiviral response; monoclonal antibodies targeting pro-inflammatory cytokines that drive the hyperinflammatory response during COVID-19 progression toward the severe stage and therapeutics that could ameliorate the function of the lungs. Furthermore, in order to help make more informed decisions on the timing of the intervention with the drugs listed in this review, we have grouped these therapeutics according to the stage of COVID-19 progression that we considered most appropriate for their mechanism of action.


  • Open Access

    Combating viral contaminants in CHO cells by engineering innate immunity

    by Austin W. T. Chiang, Shangzhong Li, Benjamin P. Kellman, Gouri Chattopadhyay, Yaqin Zhang, Chih-Chung Kuo, Jahir M. Gutierrez, Faezeh Ghazi, Hana Schmeisser, Patrice Ménard, et al.

    Viral contamination in biopharmaceutical manufacturing can lead to shortages in the supply of critical therapeutics. To facilitate the protection of bioprocesses, we explored the basis for the susceptibility of CHO cells to RNA virus infection. Upon infection with certain ssRNA and dsRNA viruses, CHO cells fail to generate a significant interferon (IFN) response. Nonetheless, the downstream machinery for generating IFN responses and its antiviral activity is intact in these cells: treatment of cells with exogenously-added type I IFN or poly I:C prior to infection limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis virus (EMCV), and Reovirus-3 virus (Reo-3) in a STAT1-dependent manner. To harness the intrinsic antiviral mechanism, we used RNA-Seq to identify two upstream repressors of STAT1: Gfi1 and Trim24. By knocking out these genes, the engineered CHO cells exhibited activation of cellular immune responses and increased resistance to the RNA viruses tested. Thus, omics-guided engineering of mammalian cell culture can be deployed to increase safety in biotherapeutic protein production among many other biomedical applications.


  • Open Access

    Combating viral contaminants in CHO cells by engineering STAT1 mediated innate immunity

    by Austin W.T. Chiang, Shangzhong Li, Benjamin P. Kellman, Gouri Chattopadhyay, Yaqin Zhang, Chih-Chung Kuo, Jahir M. Gutierrez, Faeazeh Ghazi, Hana Schmeisser, Patrice Ménard, et al.

    Viral contamination in biopharmaceutical manufacturing can lead to shortages in the supply of critical therapeutics. To facilitate the protection of bioprocesses, we explored the basis for the susceptibility of CHO cells, the most commonly used cell line in biomanufacturing, to RNA virus infection. Upon infection with certain ssRNA and dsRNA viruses, CHO cells fail to generate a significant interferon (IFN) response. Nonetheless, the downstream machinery for generating IFN responses and its antiviral activity is intact in these cells: treatment of cells with exogenously-added type I IFN or poly I:C prior to infection limited the cytopathic effect from Vesicular stomatitis virus (VSV), Encephalomyocarditis virus (EMCV), and Reovirus-3 virus (Reo-3) in a STAT1-dependent manner. To harness the intrinsic antiviral mechanism, we used RNA-Seq to identify two upstream repressors of STAT1: Gfi1 and Trim24. By knocking out these genes, the engineered CHO cells exhibited increased resistance to the prototype RNA viruses tested. Thus, omics-guided engineering of mammalian cell culture can be deployed to increase safety in biotherapeutic protein production among many other biomedical applications.